FirstWhat's of all, what is primarily needed on the prostate cancer front is an extensive and open discussion about screening benefits and risks. The US Preventive Services Task Force advises against routine screening after age 69, despite it being the second-leading cause of cancer deaths. Treatment decisions are not easy — medical advances like these are encouraging, and inevitablybetter causeresearch leadwill help to anxietyinform tricky conversations regarding this serious medical condition.

Bloomberg

Research shows that often "watchful waiting" or prostate -specific antigen is people's preferred choice over surgery given the relatively fewer chances of harm. While it might slightly increase the risk of death, it also involves fewer complications. Studies suggest surgery should be reserved for younger patients or those with aggressive cancers. Most prostate cancers grow slowly and do not cause death, supporting less aggressive treatment approaches. — something that must be factored in when assessing new me